Dazoxiben is primarily used as a thromboxane synthase inhibitor, which plays a significant role in medical research and treatment. It is particularly studied for its potential to reduce the formation of thromboxane A2, a compound that promotes blood clotting and constriction of blood vessels. This makes it a subject of interest in the management of cardiovascular diseases, such as preventing thrombosis in patients at risk of heart attacks or strokes. Additionally, it has been explored in the context of pulmonary hypertension and other conditions where blood vessel constriction is problematic. Research also examines its effects on platelet aggregation, which could be beneficial in developing treatments for disorders related to excessive clotting.